ALEXION PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)
Phase 3
Completed
- Conditions
- Myasthenia GravisMyasthenia Gravis, Juvenile FormMyasthenia Gravis, Generalized
- Interventions
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03759366
- Locations
- 🇯🇵
Research Site, Shinjuku-ku, Japan
Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
Phase 3
Completed
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- Combination Product: Ravulizumab OBDS
- First Posted Date
- 2018-11-21
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 139
- Registration Number
- NCT03748823
- Locations
- 🇹🇷
Research Site, Izmir, Turkey
Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor
Phase 4
Completed
- Conditions
- Acute Intracranial Hemorrhage
- Interventions
- Drug: Usual Care
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 530
- Registration Number
- NCT03661528
- Locations
- 🇬🇧
Research Site, Newcastle-upon-Tyne, United Kingdom
Study of Danicopan in Participants With Hepatic Impairment
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03555539
- Locations
- 🇺🇸
Clinical Trial Site, Orlando, Florida, United States
Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab
Phase 2
Completed
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Interventions
- First Posted Date
- 2018-03-21
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03472885
- Locations
- 🇬🇧
Clinical Study Site, London, United Kingdom
A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471
Phase 2
Terminated
- Conditions
- C3 GlomerulopathyImmune Complex Membranoproliferative GlomerulonephritisIC-MPGNC3 GlomerulonephritisDense Deposit Disease
- Interventions
- First Posted Date
- 2018-03-09
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT03459443
- Locations
- 🇳🇱
Clinical Study Site, Nijmegen, Netherlands
A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria
Phase 3
Completed
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- Biological: Ravulizumab
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT03406507
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease
- First Posted Date
- 2018-01-18
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 214
- Registration Number
- NCT03403205
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2017-12-27
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT03384186
- Locations
- 🇬🇧
Clinical Trial Site, Ruddington, Nottingham, United Kingdom
A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)
Phase 2
Completed
- Conditions
- C3 GlomerulopathyDense Deposit DiseaseC3 Glomerulonephritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-12-11
- Last Posted Date
- 2022-10-14
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT03369236
- Locations
- 🇬🇧
Clinical Study Site, London, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath